Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial)
Purpose To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19). Materials and methods Inclusion criteria comprised patients with COVID-19-related moderate–severe pneumonia warranting hospitalization with supplemental $ O_{2} $ and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5 Gy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24 h and 1 week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure ($ PaO_{2} $) or the pulse oximetry saturation ($ SpO_{2} $) to fractional inspired oxygen ($ FiO_{2} $) ratio of at least 20% at 24 h with respect to the preirradiation value. Results Between June and November 2020, 36 patients with COVID-19 pneumonia and a mean age of 84 years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X‑ray. All patients received dexamethasone treatment. Mean $ SpO_{2} $ pretreatment value was 94.28% and the $ SpO_{2} $/$ FiO_{2} $ ratio varied from 255 mm Hg to 283 mm Hg at 24 h and to 381 mm Hg at 1 week, respectively. In those who survived (23/36, 64%), a significant improvement was observed in the percentage of lung involvement in the CT scan at 1 week after LD-RT. No adverse effects related to radiation treatment have been reported. Conclusions LD-RT appears to be a feasible and safe option in a population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:197 |
|---|---|
| Enthalten in: |
Strahlentherapie und Onkologie - 197(2021), 11 vom: 06. Juli, Seite 1010-1020 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arenas, M. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Anti-inflammatory effects |
| Anmerkungen: |
© The Author(s) 2021. corrected publication 2021 |
|---|
| doi: |
10.1007/s00066-021-01803-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045388318 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045388318 | ||
| 003 | DE-627 | ||
| 005 | 20230519201406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211026s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00066-021-01803-3 |2 doi | |
| 035 | |a (DE-627)SPR045388318 | ||
| 035 | |a (SPR)s00066-021-01803-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.81 |2 bkl | ||
| 084 | |a 44.64 |2 bkl | ||
| 100 | 1 | |a Arenas, M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021. corrected publication 2021 | ||
| 520 | |a Purpose To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19). Materials and methods Inclusion criteria comprised patients with COVID-19-related moderate–severe pneumonia warranting hospitalization with supplemental $ O_{2} $ and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5 Gy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24 h and 1 week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure ($ PaO_{2} $) or the pulse oximetry saturation ($ SpO_{2} $) to fractional inspired oxygen ($ FiO_{2} $) ratio of at least 20% at 24 h with respect to the preirradiation value. Results Between June and November 2020, 36 patients with COVID-19 pneumonia and a mean age of 84 years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X‑ray. All patients received dexamethasone treatment. Mean $ SpO_{2} $ pretreatment value was 94.28% and the $ SpO_{2} $/$ FiO_{2} $ ratio varied from 255 mm Hg to 283 mm Hg at 24 h and to 381 mm Hg at 1 week, respectively. In those who survived (23/36, 64%), a significant improvement was observed in the percentage of lung involvement in the CT scan at 1 week after LD-RT. No adverse effects related to radiation treatment have been reported. Conclusions LD-RT appears to be a feasible and safe option in a population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities. | ||
| 650 | 4 | |a COVID-19 pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Low-dose radiation therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Treatment outcome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-inflammatory effects |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lung irradiation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Algara, M. |e verfasserin |4 aut | |
| 700 | 1 | |a De Febrer, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, X. |e verfasserin |4 aut | |
| 700 | 1 | |a de la Casa, M. A. |e verfasserin |4 aut | |
| 700 | 1 | |a Vasco, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Marín, J. |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Letón, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Villar, J. |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Royo, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Villares, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Membrive, I. |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta, J. |e verfasserin |4 aut | |
| 700 | 1 | |a López-Cano, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Araguas, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Quera, J. |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Tomás, F. |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Strahlentherapie und Onkologie |d Berlin : Springer Medizin, 1997 |g 197(2021), 11 vom: 06. Juli, Seite 1010-1020 |w (DE-627)SPR000498556 |w (DE-600)2003907-4 |x 1439-099X |7 nnns |
| 773 | 1 | 8 | |g volume:197 |g year:2021 |g number:11 |g day:06 |g month:07 |g pages:1010-1020 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00066-021-01803-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.81 |q ASE |
| 936 | b | k | |a 44.64 |q ASE |
| 951 | |a AR | ||
| 952 | |d 197 |j 2021 |e 11 |b 06 |c 07 |h 1010-1020 | ||